NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Prasugrel with percutaneous coronary intervention for treating acute coronary syndrome (review of TA182)

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsorsLilly UK (prasugrel)	General Allied Health Professionals
 Lilly UK (prasugrel) Patient/carer groups Action Heart Afiya Trust Black Health Agency Blood Pressure UK British Cardiac Patients Association Cardiac Risk in the Young Coronary Prevention Group Equalities National Council Heart Care Partnership HEART UK Independent Age Muslim Council of Britain Muslim Health Network Network of Sikh Organisations South Asian Health Foundation Specialised Healthcare Alliance Somerville Foundation Professional groups British Association for Nursing in Cardiovascular Care British Association for Services to the Elderly British Atherosclerosis Society British Cardiovascular Intervention 	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association for Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Public Health Wales NHS Trust Scottish Medicines Consortium Comparator manufacturers Actavis (aspirin, clopidogrel) Aspire Pharma (clopidogrel) AstraZeneca (Ticagrelor) Boehinringer Ingelheim (aspirin)
 Society British Cardiovascular Society British Geriatrics Society British Heart Foundation British Nuclear Cardiology Society British Society for Heart Failure 	 Beacon Pharmaceuticals (clopidogrel) Consilient Health ((clopidogrel) GlaxoSmithKline (aspirin) Intrapharm Laboratories (aspirin) Pfizer (aspirin)

National Institute for Health and Clinical Excellence

Provisional matrix for the single technology appraisal of prasugrel with percutaneous coronary intervention for treating acute coronary syndrome (review of TA182) Issue date: June 2013

Consultees Commentators (no right to submit or appeal) British Society of Cardiovascular Reckitt Benckiser (aspirin) **Imaging** Sandoz (aspirin, clopidogrel) College of Emergency Medicine Sanofi (clopidogrel) National Heart Forum Teva UK (aspirin, clopidogrel) Primary Care Cardiovascular Society The Boots Company (aspirin) Royal College of General Practitioners Thornton & Ross (aspirin) Royal College of Nursing Wockhardt UK (aspirin, Royal College of Pathologists clopidogrel) Royal College of Physicians Royal Pharmaceutical Society Relevant research groups Royal Society of Medicine Antithrombotic Trialists' (ATT) United Kingdom Clinical Pharmacy Collaboration Association British Society for Cardiovascular Vascular Society Research Cardiac and cardiology research Others dept, Barts Department of Health Central Cardiac Audit Database NHS England Cochrane Heart Group NHS Basseltlaw CCG **Cochrane Hypertension Group** NHS Fylde & Wyre CCG Cochrane Peripheral Vascular Welsh Government Diseases Group Cochrane Stroke Group CORDA European Council for Cardiovascular Research Health Research Authority MRC Clinical Trials Unit National Heart Research Fund National Institute for Health Research Research Institute for the Care of Older People Wellcome Trust Assessment Group Liverpool Reviews and Implementation Group National Institute for Health Research **Health Technology Assessment** Programme Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups

Appendix C

Consultees	Commentators (no right to submit or appeal)
	None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.